Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:873-880

This Article
Right arrow Full Text
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tilly-Kiesi, M.
Right arrow Articles by Schaefer, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tilly-Kiesi, M.
Right arrow Articles by Schaefer, E. J.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:873-880.)
© 1997 American Heart Association, Inc.


Articles

Subjects With ApoA-I(Lys107->0) Exhibit Enhanced Fractional Catabolic Rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI With AII)

Marju Tilly-Kiesi; Alice H. Lichtenstein; Jose M. Ordovas; Gregory Dolnikowski; Raija Malmström; Marja-Riitta Taskinen; ; Ernst J. Schaefer

From the Lipid Metabolism Laboratory and Mass Spectrometry Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Mass, and Helsinki University Central Hospital, Finland (M.T.-K., R.M., M.-R.T.).

Correspondence to Dr Marju Tilly-Kiesi, MD, PhD, Department of Medicine, Helsinki University Central Hospital, Haartmaninkatu 4, FIN-02900 Helsinki, Finland.

Abstract Our purpose was to examine HDL metabolism in a Finnish kindred with a 3-bp deletion in the apolipoprotein (apo) A-I gene, resulting in a deletion of Lys107 in the mature apoA-I. Patients with this mutation [apoA-I(Lys107->0)] have reduced plasma HDL cholesterol and lipoprotein (AI with AII) [Lp(AI w AII)] concentrations, but not Lp(AI) levels, compared with unaffected family members. Using primed constant infusions of [5,5,5-2H3]leucine, we determined the residence time (RT) and absolute production rate (APR) of apoA-I and apoA-II entering plasma in two subpopulations of HDL particles: [Lp(AI) and Lp(AI w AII)] in three patients heterozygous for apoA-I(Lys107->0) and in seven healthy control subjects. In patients, the mean RT of apoA-I in Lp(AI) (3.75±1.68 days) was less than half that observed in control subjects (8.01±2.51 days, P<.05). The mean RT of apoA-I in Lp(AI w AII) was also lower in patients than in control subjects, but differences were not statistically significant (4.72±2.42 versus 6.50±2.19 days). The mean RT of apoA-II in Lp(AI w AII) was significantly lower in patients (5.24±1.65 days) than in control subjects (9.64±3.57 days, P<.05). The APR of apoA-I into Lp(AI) was twofold higher in patients (5.9±2.1 mg·kg-1·d-1) than in control subjects (2.5±0.9, P<.05). The APRs of apoA-I and apoA-II into Lp(AI w AII) were similar in patients and control subjects. Our results are consistent with the concept that patients heterozygous for the apoA-I(Lys107->0) mutation have enhanced fractional catabolism of apoA-I and apoA-II in both HDL subspecies, especially in Lp(AI), and an increase in apoA-I production only into Lp(AI), which may be compensatory. Therefore, only their Lp(AI w AII) levels are decreased.


Key Words: apoA-I(Lys107->0) variant • Lp(AI with AII) • kinetics • metabolism • coronary heart disease • HDL cholesterol • Lp(AI)




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
R. Ramakrishnan
Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments
J. Lipid Res., December 1, 2006; 47(12): 2738 - 2753.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Parolini, G. Chiesa, Y. Zhu, T. Forte, S. Caligari, E. Gianazza, M. G. Sacco, C. R. Sirtori, and E. M. Rubin
Targeted Replacement of Mouse Apolipoprotein A-I with Human ApoA-I or the Mutant ApoA-IMilano. EVIDENCE OF APOA-IM IMPAIRED HEPATIC SECRETION
J. Biol. Chem., February 7, 2003; 278(7): 4740 - 4746.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
T. Oka, S. Yamashita, T. Kujiraoka, M. Ito, M. Nagano, Y. Sagehashi, T. Egashira, M. N. Nanjee, K.-i. Hirano, N. E. Miller, et al.
Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia
J. Lipid Res., August 1, 2002; 43(8): 1236 - 1243.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. Batal, M. Tremblay, L. Krimbou, O. Mamer, J. Davignon, J. Genest Jr, and J. S. Cohn
Familial HDL Deficiency Characterized by Hypercatabolism of Mature ApoA-I but Not ProApoA-I
Arterioscler. Thromb. Vasc. Biol., April 1, 1998; 18(4): 655 - 664.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Tilly-Kiesi, A. H. Lichtenstein, J. Joven, E. Vilella, M. C. Cheung, W. V. Carrasco, J. M. Ordovas, G. Dolnikowski, and E. J. Schaefer
Impact of Gender on the Metabolism of Apolipoprotein A-I in HDL Subclasses LpAI and LpAI:AII in Older Subjects
Arterioscler. Thromb. Vasc. Biol., December 1, 1997; 17(12): 3513 - 3518.
[Abstract] [Full Text]